Aims A previous association analysis identified polymorphisms in gamma-aminobutyric acid receptor A, subunit 4 (GABRA4) and GABRA2 to be associated with nicotine dependence, as assessed by a score of 4 or more on the Fagerström Test for Nicotine Dependence (FTND). In the present report, we extend the previous study by expanding our genotyping efforts significantly for these two genes. Design In 1049 cases (FTND of 4 or more) and 872 controls (smokers with FTND of 0) from the United States and Australia, we examine the association between 23 GABRA4 and 39 GABRA2 recently genotyped single nucleotide polymorphisms (SNPs) and nicotine dependence using logistic regression-based association analyses using the genomic analysis package PLINK. Results Two and 18 additional SNPs in GABRA4 and GABRA2, respectively, were associated with nicotine dependence. The SNPs identified in GABRA4 (P-value = 0.002) were restricted to introns 1 and 2, exon 1 and the 5′ end of the gene, while those in GABRA2 localized to the 3′ end of the gene and spanned introns 9-3, and were in moderate to high linkage disequilibrium (as measured by r 2 ) with each other and with previously studied polymorphisms. Conclusion Our findings demonstrate consistently the role of GABRA4 and GABRA2 in nicotine dependence. However, further research is needed to identify the biological influence of these intronic variations and to isolate functionally relevant polymorphisms neighboring them.
INTRODUCTION
Currently, several efforts are under way to identify the genetic determinants of nicotine dependence [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . We have reported previously on one such large-scale case-control study of nicotine dependence, the Nicotine Single Nucleotide Polymorphism (NICSNP) study, which included a genome-wide association and a candidate gene component [4, 5, 14] . Among the top association signals identified by the candidate gene component was a polymorphism in the gamma-aminobutyric acid receptor A, subunit 4 (GABRA4) gene. Detailed analyses of the entire family of GABA (receptors A and B) genes revealed evidence for association between nicotine dependence (FTND of 4 or more) and polymorphisms in both GABRA4 and GABRA2, both on chromosome 4p [14] .
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Due to the potential biological importance of this large family of inhibitory neurotransmitter receptors in addiction [15] [16] [17] and support for synonymous (rs279858, in GABRA2, P-value = 0.005) and non-synonymous single nucleotide polymorphisms (SNPs) (rs2229940, previously rs16859834, in GABRA4, P-value = 0.03) that were associated with nicotine dependence, we investigated these genes further. The aim of this study is to localize and delineate more clearly the association signal between nicotine dependence and GABRA2 and GABRA4 using the strategy of additional genotyping.
METHODS

Sample
The study design has been described in detail in previous publications [4, 5] . Briefly, NICSNP participants include 1050 (1049 for the present study) unrelated cases and 879 (872 for the present study) unrelated controls, selected from two independent and ongoing studies: (i) the Collaborative Genetic Study of Nicotine Dependence (COGEND), which recruited from US sites in St Louis, Detroit and Minneapolis [4] , and (ii) the Nicotine Addiction Genetics (NAG) [6] study, which included families ascertained for heavy smoking that were identified using two cohorts of the Australian Twin Panel. From both studies, only participants who had reported a history of smoking (100 or more cigarettes in their life-time), when queried by telephone interview, were eligible for inclusion in the NICSNP study. Current and life-time smokers from COGEND and NAG, respectively, with an FTND score of '0' for a self-reported period of smoking were eligible as controls. Participants reporting themselves to be current smokers with a current FTND score of 4 or greater (COGEND) or meeting this criterion for a self-reported period of heaviest smoking (NAG) were eligible as cases. Approximately 24% and 8% of the cases and controls, respectively, were drawn from the Australian sample. All subjects were of European descent. The sample included more women (52% and 66% of cases and controls, respectively) than men. Cases had a mean age of 37.7 years (range 25-82) while controls were, on average, aged 36.7 years (range 25-82). The Institutional Review Boards approved the protocol for both studies. Blood samples collected for DNA extraction were submitted along with electronic phenotypic and genetic data for both studies to the National Institute on Drug Abuse (NIDA) Center for Genetic Studies, which manages the sharing of research data according to guidelines of the National Institutes of Health.
Genotyping
During the first phase, genotyping was conducted by Perlegen Sciences using custom-designed high-density oligonucleotide assays [4] . During that phase of genotyping, six and 27 SNPs were typed in GABRA2 and GABRA4, respectively. Through a competitive application to the Center for Inherited Diseases Research (CIDR), we further genotyped 1049 (of 1050) cases and 872 (of 879) controls. A total of 62 new SNPs were typed, including 39 in GABRA2 (of 42 attempted) and 23 in GABRA4.
Only SNPs with call rates of 98% and greater were included in this phase of data analysis, thus asserting a higher level of quality control on these data (Table 1) .
Association analyses
Association analyses were conducted on the 62 CIDR SNPs. A logistic regression model, which has been described previously by Saccone et al. [5] , was implemented in the genomic analysis package PLINK [18] , with controls for sex (0 = male, 1 = female) and site (1 = Australia, 0 = United States, as a disproportionate number of cases and controls come from each site). The model tested the influence of an additive genotypic model, where 0 = no copies of the minor allele, 1 = one copy of the minor allele and 2 = both copies of the minor allele, on a dichotomous measure of case status. As in our previous study, an interaction between genotype and sex was also included. The Benjamini-Hochberg false discovery rate (FDR-BH, [19] ) P-value was also computed for the effect of genotype.
HAPLOVIEW [20] was used to examine the extent of linkage disequilibrium, as indexed by r 2 , across the combined CIDR and previously typed Perlegen SNPs [14] .
RESULTS
Association results are presented in Table 2 (GABRA2) and 3 (GABRA4)-we focus upon results emerging from the newly genotyped SNPs, but to provide a comprehensive view of this association finding, results from previous analyses (originally published in [14] ) are also presented in the tables. Sex (males being more likely to be cases) and site (Australia: this sample provided nearly three times as many cases as controls) had important main effects.
GABRA2
Of the 39 newly genotyped SNPs, 19 SNPs (Table 2) were associated with case status (FTND scores of 4+) at P-values less than 0.01. Even after correcting for multiple testing, the FDR-BH P-values were less than 0.05. An additional five SNPs were associated marginally at P-values less than 0.05. Association extended from the 3′ end of the gene to intron 3. Overall, the SNPs contributing to the association signal, including newly and previously typed polymorphisms, were in moderate to high linkage disequilibrium (LD) (r 2 ranging from 0.75-0.99, 
GABRA4
Only two of the newly genotyped SNPs, rs10517173, rs16851647, were associated with nicotine dependence (observed P-values of 0.002, corrected FDR-BH P-values of 0.02). However, these SNPs were in complete LD (r 2 = 1, Fig. S2 ; see Supporting Information) with each other and with rs11731576. Thus, the signal tagged by the newly genotyped SNPs represented association at the same underlying locus identified by us previously. Association was restricted to introns 2 and 1 and the intervening exon and extended toward the 5′ end of the gene. Interactions with sex were marginally significant, suggesting again that these SNPs may exert a more potent influence in men versus women.
DISCUSSION
The current analyses provide compelling additional evidence for the association between SNPs in the GABRA2 and GABRA4 genes and nicotine dependence as assessed by the FTND. Some caveats and limitations of our study should be considered: first, these results are specific to our case-control definition-the intention of this study was to examine genes associated with progression in regular smokers and, thus, the controls in this study are regular smokers without a history of nicotine dependence (not even one symptom reported in a telephone interview) as assessed by the FTND. Secondly, our results are from a sample of European descent, and further study is needed to determine whether they extend to other ethnicities. Thirdly, it is important to consider the issue of multiple testing. In the context of the larger candidate gene study, these signals may not meet criteria for statistical significance. Within the context of these analyses, the FDR-BH P-values presented in Tables 2 and 3 suggest that a reasonable proportion of our signals are likely to be true positives.
Some have argued that additional genotyping of SNPs in moderate to high LD with previously genotyped markers is not an efficient strategy. However, evidence for LD is not necessarily synonymous with correlated evidence for association. Nielsen et al. [21] have demonstrated that in the presence of an observed signal, the relationship between association test results and intermarker LD is related to several factors, including LD between each SNP and the functional site, multi-SNP LD and the genetic model. Due to the complexities inherent in the etiology of polygenic, multi-factorial phenotypes, such as nicotine dependence, we opted to proceed to the stage of additional genotyping. This is, undoubtedly, only the first step towards understanding how genes constituting the GABAergic system influence vulnerability to smoking. Our next steps will include efforts to identify functional variants within these genes (and in neighboring regions), their impact on gene expression and, importantly, how environmental influences interact with these genomic variations. We also look forward to replication of our findings via independent efforts allowing for greater confidence in the role of GABRA2 and GABRA4 in the etiology of nicotine dependence. 
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